Leukocyte and Dried Blood Spot Arylsulfatase A Assay by Tandem Mass Spectrometry.

Abstract

Liquid chromatography-tandem mass spectrometry (LC-MS/MS) assays were developed to measure arylsulfatase A (ARSA) activity in leukocytes and dried blood spots (DBS) using deuterated natural sulfatide substrate. These new assays were highly specific and sensitive. Patients with metachromatic leukodystrophy (MLD) and multiple sulfatase deficiency (MSD) displayed a clear deficit in the enzymatic activity and could be completely distinguished from normal controls. The leukocyte assay reported here will be important for diagnosing MLD and MSD patients and for monitoring the efficacy of therapeutic treatments. ARSA activity was measured in DBS for the first time without an antibody. This new ARSA DBS assay can serve as a second-tier test following the sulfatide measurement in DBS for newborn screening of MLD. This leads to an elimination of most of the false positives identified by the sulfatide assay.

Department

Description

Provenance

Citation

Published Version (Please cite this version)

10.1021/acs.analchem.9b05274

Publication Info

Hong, Xinying, Arun Babu Kumar, Jessica Daiker, Fan Yi, Martin Sadilek, Fabiola De Mattia, Francesca Fumagalli, Valeria Calbi, et al. (2020). Leukocyte and Dried Blood Spot Arylsulfatase A Assay by Tandem Mass Spectrometry. Analytical chemistry, 92(9). pp. 6341–6348. 10.1021/acs.analchem.9b05274 Retrieved from https://hdl.handle.net/10161/24564.

This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.


Unless otherwise indicated, scholarly articles published by Duke faculty members are made available here with a CC-BY-NC (Creative Commons Attribution Non-Commercial) license, as enabled by the Duke Open Access Policy. If you wish to use the materials in ways not already permitted under CC-BY-NC, please consult the copyright owner. Other materials are made available here through the author’s grant of a non-exclusive license to make their work openly accessible.